Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors

References

• Nunez-Navarro NE, Santana FM, Parra LP, et al. Surfing the blood coagulation cascade: insight into the vital factor Xa. Curr Med Chem. 2018 Jan 25. Epub ahead of print. DOI:10.2174/0929867325666180125165340.
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Smallheer JM, Cheney DL, et al. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem. 2010;53(17):6243–6274.
   PubMed Web of Science ®Google Scholar
• Fischer PM. Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs. J Med Chem. 2018;61(9):3799–3822.
   PubMed Web of Science ®Google Scholar
• Xie Z, Tian Y, Lv X, et al. The selectivity and bioavailability improvement of novel oral anticoagulants: an overview. Eur J Med Chem. 2018;146:299–317.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost. 2017;117(7):1283–1288.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017;12(12):1195–1205.
   PubMed Web of Science ®Google Scholar
• Dudley DA, Bunker AM, Chi L, et al. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. J Med Chem. 2000;43(22):4063–4070.
   PubMed Web of Science ®Google Scholar
• Herron DK, Goodson T Jr, Wiley MR, et al. 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J Med Chem. 2000;43(5):859–872.
   PubMed Web of Science ®Google Scholar
• Hirayama F, Koshio H, Ishihara T, et al. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as an efficacious and orally available factor Xa inhibitor. J Med Chem. 2011;54(23):8051–8065.
   PubMed Web of Science ®Google Scholar
• Zbinden KG, Anselm L, Banner DW, et al. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Eur J Med Chem. 2009;44(7):2787–2795.
   PubMed Web of Science ®Google Scholar
• Ye B, Arnaiz DO, Chou YL, et al. Thiophene-anthranilamides as highly efficacious and orally available factor Xa inhibitors. J Med Chem. 2007;50(13):2967–2980.
   PubMed Web of Science ®Google Scholar
• Zuo X, Huo Z, Kang D, et al. Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017). Expert Opin Ther Pat. 2018;28(4):299–316.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005–2010). Expert Opin Ther Pat. 2011;21(5):717–796.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Pat. 2014;24(11):1199–1227.
   PubMed Web of Science ®Google Scholar
• Song Y, Fang Z, Zhan P, et al. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009–2013 update. Curr Med Chem. 2014;21(3):329–355.
   PubMed Web of Science ®Google Scholar
• Wiley MR, Weir LC, Briggs S, et al. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J Med Chem. 2000;43(5):883–899.
   PubMed Web of Science ®Google Scholar
• Corte JR, Fang T, Pinto DJ, et al. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties. Bioorg Med Chem Lett. 2008;18(9):2845–2849.
   PubMed Web of Science ®Google Scholar
• Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009;19(8):2179–2185.
   PubMed Web of Science ®Google Scholar
• Sagi K, Nakagawa T, Yamanashi M, et al. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. J Med Chem. 2003;46(10):1845–1857.
   PubMed Web of Science ®Google Scholar
• Nazaré M, Will DW, Matter H, et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. J Med Chem. 2005;48(14):4511–4525.
   PubMed Web of Science ®Google Scholar
• Guertin KR, Gardner CJ, Klein SI, et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg Med Chem Lett. 2002;12(12):1671–1674.
   PubMed Web of Science ®Google Scholar
• Imaeda Y, Kuroita T, Sakamoto H, et al. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors. J Med Chem. 2008;51(12):3422–3436.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Imaeda Y, Konishi N, et al. Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor. J Med Chem. 2010;53(9):3517–3531.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Bates ER, Bhatt DL, et al. AXIOM investigators. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thromb Haemost. 2014;111(6):1141–1152.
   PubMed Web of Science ®Google Scholar
• Qiao JX, Cheney DL, Alexander RS, et al. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of factor Xa. Bioorg Med Chem Lett. 2008;18(14):4118–4123.
   PubMed Web of Science ®Google Scholar
• Quan ML, Pinto DJ, Rossi KA, et al. Phenyltriazolinones as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2010;20(4):1373–1377.
   PubMed Web of Science ®Google Scholar
• Van Huis CA1, Casimiro-Garcia A, Bigge CF, et al. Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active factor Xa inhibitors with extended duration of action. Bioorg Med Chem. 2009;17(6):2501–2511.
   PubMed Web of Science ®Google Scholar
• Choi-Sledeski YM, McGarry DG, Green DM, et al. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization. J Med Chem. 1999;42(18):3572–3587.
   PubMed Web of Science ®Google Scholar
• Watson NS, Brown D, Campbell M, et al. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. Bioorg Med Chem Lett. 2006;16(14):3784–3788.
   PubMed Web of Science ®Google Scholar
• Young RJ, Campbell M, Borthwick AD, et al. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Bioorg Med Chem Lett. 2006;16(23):5953–5957.
   PubMed Web of Science ®Google Scholar
• Chan C, Borthwick AD, Brown D, et al. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. J Med Chem. 2007;50(7):1546–1557.
   PubMed Web of Science ®Google Scholar
• Young RJ, Brown D, Burns-Kurtis CL, et al. Selective and dual action orally active inhibitors of thrombin and factor Xa. Bioorg Med Chem Lett. 2007;17(10):2927–2930.
   PubMed Web of Science ®Google Scholar
• Young RJ, Borthwick AD, Brown D, et al. Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. Bioorg Med Chem Lett. 2008;18(1):28–33.
   PubMed Web of Science ®Google Scholar
• Kleanthous S, Borthwick AD, Brown D, et al. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. Bioorg Med Chem Lett. 2010;20(2):618–622.
   PubMed Web of Science ®Google Scholar
• Young RJ, Adams C, Blows M, et al. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. Bioorg Med Chem Lett. 2011;21(6):1582–1587.
   PubMed Web of Science ®Google Scholar
• Watson NS, Adams C, Belton D, et al. The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. Bioorg Med Chem Lett. 2011;21(6):1588–1592.
   PubMed Web of Science ®Google Scholar
• Young RJ, Borthwick AD, Brown D, et al. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. Bioorg Med Chem Lett. 2008;18(1):23–27.
   PubMed Web of Science ®Google Scholar
• Salonen LM1, Holland MC, Kaib PS, et al. Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water. Chemistry. 2012;18(1):213–222.
   PubMed Web of Science ®Google Scholar
• Schärer K, Morgenthaler M, Paulini R, et al. Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. Angew Chem Int Ed Engl. 2005;44(28):4400–4404.
   PubMed Web of Science ®Google Scholar
• Salonen LM, Bucher C, Banner DW, et al. Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. Angew Chem Int Ed Engl. 2009;48(4):811–814.
   PubMed Web of Science ®Google Scholar
• Stumpfe D, Bajorath J. Exploring activity cliffs in medicinal chemistry. J Med Chem. 2012;55:2932–2942.
   PubMed Web of Science ®Google Scholar
• Stumpfe D, Hu Y, Dimova D, et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. J Med Chem. 2014;57:18–28.
   PubMed Web of Science ®Google Scholar
• Lu X, Li X, Yang J, et al. Arylazolyl(azinyl)thioacetanilides. Part 20: discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorg Med Chem. 2016;24(18):4424–4433.
   PubMed Web of Science ®Google Scholar
• Li X, Huang B, Zhou Z, et al. Arylazolyl(azinyl)thioacetanilides: part 19: discovery of novel substituted imidazo[4,5-b]pyridin-2-ylthioacetanilides as potent HIV NNRTIs via a structure-based bioisosterism approach. Chem Biol Drug Des. 2016;88(2):241–253.
   PubMed Web of Science ®Google Scholar
• Li X, Lu X, Chen W, et al. Arylazolyl(azinyl)thioacetanilides. Part 16: structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorg Med Chem. 2014;22(19):5290–5297.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen W, Li Z, et al. Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorg Med Chem. 2012;20(23):6795–6802.
   PubMed Web of Science ®Google Scholar
• Zhan P, Li X, Li Z, et al. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorg Med Chem Lett. 2012;22(23):7155–7162.
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Kobayashi S, Nakamoto Y, et al. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6–6 fused rings as alternative S1 moieties. Bioorg Med Chem. 2009;17(24):8221–8233.
   PubMedGoogle Scholar
• Kucznierz R1, Grams F, Leinert H, et al. Tetrahydro-isoquinoline-based factor Xa inhibitors. J Med Chem. 1998;41(25):4983–4994.
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Wang S, et al. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2ʹ-(methylsulfonyl)-[1,1ʹ-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2001;44(4):566–578.
   PubMed Web of Science ®Google Scholar
• Haginoya N1, Kobayashi S, Komoriya S, et al. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. J Med Chem. 2004;47(21):5167–5182.
   PubMed Web of Science ®Google Scholar
• Yee YK, Tebbe AL, Linebarger JH, et al. N(2)-Aroylanthranilamide inhibitors of human factor Xa. J Med Chem. 2000;43(5):873–882.
   PubMed Web of Science ®Google Scholar
• Shi Y, O’Connor SP, Sitkoff D, et al. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors. Bioorg Med Chem Lett. 2011;21(24):7516–7521.
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Yoshino T, Yokomizo Y, et al. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors. Bioorg Med Chem Lett. 2011;21(7):2133–2140.
   PubMed Web of Science ®Google Scholar
• Kohrt JT, Filipski KJ, Cody WL, et al. The discovery of glycine and related amino acid-based factor Xa inhibitors. Bioorg Med Chem. 2006;14(13):4379–4392.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang J, Shi M, et al. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett. 2009;19(15):4034–4041.
   PubMed Web of Science ®Google Scholar
• Senger S, Convery MA, Chan C, et al. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors. Bioorg Med Chem Lett. 2006;16(22):5731–5735.
   PubMed Web of Science ®Google Scholar
• Hu Y, Stumpfe D, Bajorath J. Recent advances in scaffold hopping. J Med Chem. 2017;60(4):1238–1246.
   PubMed Web of Science ®Google Scholar
• Li X, Zhan P, Liu H, et al. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg Med Chem. 2012;20(18):5527–5536.
   PubMed Web of Science ®Google Scholar
• Han Q, Dominguez C, Stouten PF, et al. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. J Med Chem. 2000;43(23):4398–4415.
   PubMed Web of Science ®Google Scholar
• Phillips GB, Buckman BO, Davey DD, et al. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem. 1998;41(19):3557–3562.
   PubMed Web of Science ®Google Scholar
• Adler M1, Davey DD, Phillips GB, et al. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry. 2000;39(41):12534–12542.
   PubMed Web of Science ®Google Scholar
• Phillips G, Davey DD, Eagen KA, et al. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J Med Chem. 1999;42(10):1749–1756.
   PubMed Web of Science ®Google Scholar
• Ewing WR, Becker MR, Manetta VE, et al. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999;42(18):3557–3571.
   PubMed Web of Science ®Google Scholar
• Qiao JX, Chang CH, Cheney DL, et al. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation factor Xa. Bioorg Med Chem Lett. 2007;17(16):4419–4427.
   PubMed Web of Science ®Google Scholar
• Nagata T, Yoshino T, Haginoya N, et al. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors. Bioorg Med Chem Lett. 2007;17(16):4683–4688.
   PubMed Web of Science ®Google Scholar
• Anselm L, Banner DW, Benz J, et al. Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate. Bioorg Med Chem Lett. 2010;20(17):5313–5319.
   PubMed Web of Science ®Google Scholar
• Lazar C, Kluczyk A, Kiyota T, et al. Drug evolution concept in drug design: 1. Hybridization method. J Med Chem. 2004;47(27):6973–6982.
   PubMed Web of Science ®Google Scholar
• Huang B, Wang X, Liu X, et al. Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorg Med Chem. 2017 Aug 15;25(16):4397–4406.
   PubMed Web of Science ®Google Scholar
• Zhang H, Tian Y, Kang D, et al. Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. Eur J Med Chem. 2017;130:209–222.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen W, Zhan P, et al. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur J Med Chem. 2014;87:52–62.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan P, Rai D, et al. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorg Med Chem. 2014;22(6):1863–1872.
   PubMed Web of Science ®Google Scholar
• Choi-Sledeski YM, Kearney R, Poli G, et al. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J Med Chem. 2003;46(5):681–684.
   PubMed Web of Science ®Google Scholar
• Komoriya S, Haginoya N, Kobayashi S, et al. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg Med Chem. 2005;13(12):3927–3954.
   PubMed Web of Science ®Google Scholar
• Adler M1, Kochanny MJ, Ye B, et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry. 2002;41(52):15514–15523.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang B, Suzuki T, et al. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics. 2015;7(8):1379–1396.
   PubMed Web of Science ®Google Scholar
• Zhan P, Song Y, Itoh Y, et al. Recent advances in the structure-based rational design of TNKSIs. Mol Biosyst. 2014;10(11):2783–2799.
   PubMedGoogle Scholar
• Zhang S, Zhang J, Gao P, et al. Efficient drug discovery by rational lead hybridization based on crystallographic overlay. Drug Discov Today. 2019;24(3):805–813.
   PubMed Web of Science ®Google Scholar
• Fang Z, Song Y, Zhan P, et al. Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery. Future Med Chem. 2014;6(8):885–901.
   PubMed Web of Science ®Google Scholar
• Hirayama F1, Koshio H, Katayama N, et al. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template. Bioorg Med Chem. 2003;11(3):367–381.
   PubMed Web of Science ®Google Scholar
• Pruitt JR, Pinto DJ, Galemmo RA Jr, et al. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2ʹ-(aminosulfonyl)[1,1ʹ-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J Med Chem. 2003;46(25):5298–5315.
   PubMed Web of Science ®Google Scholar
• Quan ML, Lam PY, Han Q, et al. Discovery of 1-(3ʹ-aminobenzisoxazol-5ʹ-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2ʹ-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem. 2005;48(6):1729–1744.
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Quan ML, et al. 1-[3-Aminobenzisoxazol-5ʹ-yl]-3-trifluoromethyl-6-[2ʹ-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1ʹ]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett. 2006;16(15):4141–4147.
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Galemmo RA Jr, Quan ML, et al. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. Bioorg Med Chem Lett. 2006;16(21):5584–5589.
   PubMed Web of Science ®Google Scholar
• Pinto DJ1, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339–5356.
   PubMed Web of Science ®Google Scholar
• Lee YK, Parks DJ, Lu T, et al. 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem. 2008;51(2):282–297.
   PubMed Web of Science ®Google Scholar
• Xue T, Ding S, Guo B, et al. Design, synthesis, and structure-activity and structure-PK relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. J Med Chem. 2014;57(18):7770–7791.
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59–7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900–5908.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kaur J, Wuest M, et al. In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nat Commun. 2017;8:1.
   PubMed Web of Science ®Google Scholar
• Zhan P, Pannecouque C, De Clercq E, et al. Anti-HIV Drug Discovery and Development: current Innovations and Future Trends. J Med Chem. 2016;59(7):2849–2878.
   PubMed Web of Science ®Google Scholar
• Zhan P, Itoh Y, Suzuki T, et al. Strategies for the discovery of target-specific or isoform-selective modulators. J Med Chem. 2015;58(19):7611–7633.
   PubMed Web of Science ®Google Scholar
• Jaegle M, Steinmetzer T, Rademann J. Protein-templated formation of an inhibitor of the blood coagulation factor Xa through a background-free amidation reaction. Angew Chem Int Ed Engl. 2017;56(13):3718–3722.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des. 2009;15(16):1893–1917.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Rationally designed multitarget anti-HIV agents. Curr Med Chem. 2013;20(13):1743–1758.
   PubMed Web of Science ®Google Scholar
• Meneyrol J, Follmann M, Lassalle G, et al. 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor. J Med Chem. 2013;56(23):9441–9456.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev. 2013;33(Suppl 1):E1–72.
   PubMed Web of Science ®Google Scholar
• Nazaré M, Matter H, Will DW, et al. Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. Angew Chem Int Ed Engl. 2012;51(4):905–911.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim H, Park SB. Privileged structures: efficient chemical “navigators” toward unexplored biologically relevant chemical spaces. J Am Chem Soc. 2014;136(42):14629–14638.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang B, Liu X, et al. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discov Today. 2016;21(1):118–132.
   PubMed Web of Science ®Google Scholar
• Segall M. Advances in multiparameter optimization methods for de novo drug design. Expert Opin Drug Discov. 2014;9:803–817.
   PubMed Web of Science ®Google Scholar
• Wager TT, Kormos BL, Brady JT, et al. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J Med Chem. 2013;56:9771–9779.
   PubMed Web of Science ®Google Scholar
• Quan ML, Pinto DJP, Smallheer JM, et al. Factor XIa inhibitors as new anticoagulants. J Med Chem. 2018;61(17):7425–7447.
   PubMed Web of Science ®Google Scholar
• Swedberg JE, Mahatmanto T, Abdul Ghani H, et al. Substrate-guided design of selective FXIIa inhibitors based on the plant-derived momordica cochinchinensis trypsin inhibitor-II (MCoTI-II) scaffold. J Med Chem. 2016;59(15):7287–7292.
   PubMed Web of Science ®Google Scholar